Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Gilberto Lopes(University of Miami), Pui San Tan(University of Oxford), Sarah Simko(University of Miami), Bárbara de Souza Gutierres(Universidade Paulista), Auro del Giglio(Faculdade de Medicina do ABC), Carmélia Maria Noia Barreto(Instituto de Medicina Avançada)
Einstein (São Paulo)
February 25, 2019
10.31744/einstein_journal/2019gs4414
Cited by 19

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334
The biology of cancer-related fatigue: a review of the literature
|Supportive Care in Cancer|2015|305